One autologous clinical trial (NCT05566223) uses CRISPR-Cas9 to knockout the CISH (Cytokine-induced SH2 protein) gene in tumor infiltrating lymphocytes (TILs), a type of T cell that penetrates solid tumors. This evidence concerns the gene CISH and neoplasm.